ObjectiveTo devise strategies to amend lay and practitioner atopic eczema mindlines ‘collectively reinforced, internalised tacit guidelines’, to improve consultation experiences and self-management practices in primary care.DesignCo-creation workshops informed by the Co:Create Coproduction Matrix.SettingConference centre in central England and via remote communication.ParticipantsLay people with, and parents of children with, atopic eczema, practitioners, a researcher and a facilitator (n=22).ResultsEczema mindline amendment needs to address people and parents of children with the condition, practitioners and wider society in parallel. For lay people trust and ‘realness’ of amendment activity was vital and practitioners wanted practical, locally relevant, hints and tips, tailored, ‘no faff’ approaches. To improve consultation experiences and self-management practices, five key, consistent, evidence-based messages need to be instilled into eczema mindlines: (1) eczema is more than just dry skin, (2) eczema does not just go away, (3) moisturisers are for every day, (4) steroid creams are okay when you need them and (5) you know your child’s eczema best.ConclusionThis co-creation study provides original insights into what eczema knowledge should be mobilised, who needs to have this knowledge, how this should be achieved to amend existing mindlines to improve consultation experiences and self-management practices in primary care.The remaining challenge is to refine, implement and evaluate the effectiveness of strategies developed to instil the five core messages and erase outdated or inaccurate information.

The UK Dermatology Clinical Trials Network (UK DCTN) was established in 2002 to address our collective ignorance on the treatment of skin disease. Although started with just a good idea and goodwill, the UK DCTN has grown into a UK-wide collaborative group of over 600 members running five fully funded clinical trials. The aim of the UK DCTN is simple: to conduct high quality, independent, multicenter, randomized controlled clinical trials for the prevention or treatment of skin disease. This article describes how the UK DCTN was set up, how such firm foundations have helped it grow and future plans to extend the concept globally. We hope this will be useful to others developing research networks in smaller clinical specialties and other countries.

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

No abstract

Collaborative clinician-led research networks Editor-We commend Rajasekhar et al on their development of the Northern Region Endoscopy Group (NREG) in 2007 (Clin Med April 2014 pp 107-12) to facilitate high-quality, multicentre research, service improvement and audit activity within endoscopic practice in their region. The nature of their collaborative research is familiar to dermatology through the 'UK Dermatology Clinical Trials Network' (UK DCTN), 1 which was formed fi ve years prior to the NREG with the aim of prioritising and developing independent, high-quality clinical trials for people with skin diseases. The UK DCTN now comprises a multidisciplinary membership of over 750 dermatologists, dermatology nurses, health services researchers, patients and carers. Trial suggestions from UK DCTN members are prioritised and developed using a rigorous and predefi ned process. 2 Funding for individual studies arises from external grant applications made to the National Institute of Health Research (NIHR) and charitable bodies. The UK DCTN has been successful in securing over £8 million in independent funding over the last 10 years and to date has completed four multicentre randomised controlled trials, all of which have resulted in high-profi le publications. An example is the prophylactic antibiotics for the treatment of cellulitis at home (PATCH) (penicillin to prevent recurrent leg cellulitis) study. 3 Other studies are currently either in development or are open to recruitment. This method of working has been particularly benefi cial in the research of rare conditions whereby multicentre input is paramount in recruitment of adequate participant numbers. The importance of building research capacity among healthcare professionals is recognised through an annual award scheme, which is open to trainees, staff and associate specialist doctors, general practitioners and nurses, and the formation of a UK DCTN Trainee Group, which is led by former trainee award holders. An extension to the success of our UK DCTN initiative is the International Federation of Dermatology Clinical Trial Networks (IF DCTN). 4 This network aims to share good practice in performing independent dermatology clinical trials internationally, to improve the quality of design and reporting of dermatology clinical trials, and to collaborate on undertaking clinical trials of rare skin diseases across the world.